SFSIG
HEPA

San Francisco Sentry Investment Group’s Hepion Pharmaceuticals HEPA Stock Holding History

San Francisco Sentry Investment Group’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$20K Hold
10
– – 0.01% 475
2021
Q1 		$18K Buy
+10
New +$21.9K 0.01% 501

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

San Francisco Sentry Investment Group's HEPA Position: Q2 2021 in Review

San Francisco Sentry Investment Group held its Hepion Pharmaceuticals (HEPA) position steady in Q2 2021 at 10 shares worth $20K. The position accounts for 0.01% of the portfolio, ranked #475.

San Francisco Sentry Investment Group first reported a position in HEPA in Q1 2021 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold HEPA as of Q2 2021.

  • San Francisco Sentry Investment Group held 10 shares of Hepion Pharmaceuticals worth $20K as of Q2 2021.
  • San Francisco Sentry Investment Group left its Hepion Pharmaceuticals share count unchanged in Q2 2021.
  • Hepion Pharmaceuticals made up 0.01% of San Francisco Sentry Investment Group's portfolio in Q2 2021, its #475 holding.
  • San Francisco Sentry Investment Group first reported a position in Hepion Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.